Abstract: Targeted therapy of non-small cell lung cancer (NSCLC) has become a focus in recent years and is based on accurate detection of the molecular phenotype of a tumor. The anaplastic lymphoma kinase (ALK) gene rearrangement is an important subtype of lung cancer gene mutation. A variety of ALK inhibitors have been used in clinical practice and have demonstrated good therapeutic effects. As a routine, convenient, and non-invasive method, imaging examination is of great value for the diagnosis and treatment of tumors. Imaging features have a predictive value for ALK gene rearrangement in NSCLC. In this study, ALK rearrangement and its association with imaging features in NSCLC were described.